Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.67 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.60 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.60 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | P2RY10 | O00398 | 6/20 | 0.47 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.47 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.47 |
| ▸ | FABP3 | P05413 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962151 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL12345678 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL2233966 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL12345664 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL15166560 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL12345694 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL705428 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL2175237 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL703055 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 | |
| SCHEMBL12345706 | 1.00 | PLA2G2C (0.67) | PLA2G2CLPAR1LPAR3LPAR2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206206-B2 | Oxidized lipid compounds and uses thereof | VASCULAR BIOGENICS LTD. (IL) | 2015-12-08 | — | — | US | disclosed |
| EP-2826370-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2826369-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2348866-B1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD (IL) | 2015-01-07 | — | — | EP | disclosed |
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | VASCULAR BIOGENICS LTD. (IL) | 2013-08-08 | — | — | US | disclosed |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | LPO, GPX4, ALOX15B | PLA2G2C 1093/4885LPAR1 305/4885LPAR3 417/4885 |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | LPO, GPX4, ALOX15B | PLA2G2C 1093/4885LPAR1 305/4885LPAR3 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.